Serebruany V.; Kim M.; Cabrera-Fuentes H.; Lee K.; Cho Y.; Park K.; Park T.; Kim Y.; Yoon S.
(2017)
© Schattauer 2017.The optimal duration and cancer risks of antiplatelet therapy following percutaneous coronary intervention (PCI) are unclear. We compared cancer and all-cause mortality after dual antiplatelet therapy ...